March 24 (Reuters) - Allogene Therapeutics Inc:
* MAXCYTE AND ALLOGENE THERAPEUTICS SIGN CLINICAL AND COMMERCIAL LICENSE AGREEMENT TO ENABLE THE ADVANCEMENT OF ALLOGENEIC CAR T (ALLOCAR T™) THERAPIES
* ALLOGENE THERAPEUTICS - AGREEMENT ENABLES ALLOGENE TO UTILIZE MAXCYTE’S EXPERT PLATFORM IN TARGET CANDIDATES
* ALLOGENE THERAPEUTICS INC - UNDER TERMS, MAXCYTE TO GET UNDISCLOSED DEVELOPMENT, APPROVAL & COMMERCIAL MILESTONES IN ADDITION TO OTHER LICENSING FEES Source text for Eikon: Further company coverage:
